| scholarly article | Q13442814 |
| P2093 | author name string | Vivian A Fonseca | |
| Gandahari Rosa A Carpio | |||
| P2860 | cites work | Incidence of lactic acidosis in metformin users | Q22241284 |
| Metformin | Q22250907 | ||
| Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus | Q22253064 | ||
| Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study | Q24601415 | ||
| Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study | Q24654974 | ||
| Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis | Q24655666 | ||
| Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy | Q28279020 | ||
| Standards of medical care in diabetes--2014 | Q28304435 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight | Q31362282 | ||
| Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin | Q31439640 | ||
| Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus | Q33470746 | ||
| The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone | Q33486737 | ||
| Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits | Q33602360 | ||
| Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus | Q33736122 | ||
| Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence | Q33854022 | ||
| A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials | Q33874163 | ||
| Comparative tolerability of sulphonylureas in diabetes mellitus | Q33903076 | ||
| Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes | Q33932712 | ||
| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes | Q34227891 | ||
| Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment | Q34292318 | ||
| The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients | Q34329426 | ||
| A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. | Q34421364 | ||
| Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). | Q34587610 | ||
| Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial | Q34593046 | ||
| Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone | Q34613240 | ||
| Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy | Q34616881 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Metformin-associated lactic acidosis: case reports and literature review. | Q34873847 | ||
| Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 | ||
| Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting | Q35043204 | ||
| Biguanide-associated lactic acidosis. Case report and review of the literature | Q35534961 | ||
| Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association | Q35615572 | ||
| Association of biochemical B₁₂ deficiency with metformin therapy and vitamin B₁₂ supplements: the National Health and Nutrition Examination Survey, 1999-2006. | Q35688240 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 | ||
| Oral antihyperglycemic agents and renal disease: new agents, new concepts | Q36153042 | ||
| Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis | Q36247512 | ||
| Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus | Q36899187 | ||
| Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials | Q36955489 | ||
| Insulin-associated weight gain in diabetes--causes, effects and coping strategies | Q36966075 | ||
| New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications | Q37062723 | ||
| Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting | Q37583129 | ||
| The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review | Q37864256 | ||
| The safety of incretin-based therapies--review of the scientific evidence | Q37898348 | ||
| Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines | Q37922124 | ||
| Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. | Q38325827 | ||
| Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial | Q39236644 | ||
| Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. | Q39732229 | ||
| A review of the safety and efficacy of acarbose in diabetes mellitus | Q41184991 | ||
| Oral antidiabetic drugs: an overview | Q41190719 | ||
| Sitagliptin-associated drug allergy: review of spontaneous adverse event reports | Q42972433 | ||
| Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes | Q42999133 | ||
| Acute renal failure from contrast medium: beware patients taking metformin... | Q43252222 | ||
| Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan | Q43588086 | ||
| Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet | Q44648280 | ||
| Comparing diabetes drugs--helping clinical decisions? | Q44669438 | ||
| Second-generation thiazolidinediones and hepatotoxicity | Q44987602 | ||
| Metformin monitoring and change in serum creatinine levels in patients undergoing radiologic procedures involving administration of intravenous contrast media | Q45037776 | ||
| Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes | Q45330821 | ||
| Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption | Q46592677 | ||
| Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis | Q46625495 | ||
| Hepatotoxicity associated with acarbose therapy | Q46827246 | ||
| Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis | Q47613876 | ||
| Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. | Q51337136 | ||
| Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee. | Q53345648 | ||
| Chlorpropamide hyponatremia: drug-induced inappropriate antidiuretic-hormone activity. | Q54322618 | ||
| Thiazolidinediones and Heart Failure: A teleo-analysis | Q57413498 | ||
| Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study | Q59624425 | ||
| Acarbose-associated hepatotoxicity | Q60344802 | ||
| Diarrhea and Metformin in a Diabetic Clinic | Q70236152 | ||
| Chlorpropamide-induced hyponatremia: incidence and risk factors | Q70521161 | ||
| Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis | Q70806623 | ||
| Metformin-associated lactic acidosis | Q71208313 | ||
| Thiazolidinediones | Q73740397 | ||
| Thiazolidinediones and the risk of edema: a meta-analysis | Q79283695 | ||
| Exenatide and rare adverse events | Q94699384 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 92-100 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Diabetes spectrum : a publication of the American Diabetes Association | Q27722982 |
| P1476 | title | Update on Safety Issues Related to Antihyperglycemic Therapy | |
| P478 | volume | 27 |
| Q38546214 | Adverse Effects Associated With Newer Diabetes Therapies |
| Q92025124 | Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health? |
| Q50315166 | Hypoglycemic and hypolipidemic activity of aqueous leaf extract of Passiflora suberosa L. |
| Q47283908 | Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications |
Search more.